What is the core difference between sermorelin and ipamorelin?
Both peptides are growth-hormone secretagogues — compounds that prompt the pituitary gland to release more of the body's own growth hormone (GH) rather than injecting GH directly. The key difference is the door each one knocks on.
Sermorelin is an analog of growth hormone-releasing hormone (GHRH). It reproduces the active first 29 amino acids of natural GHRH and binds the GHRH receptor on the pituitary, nudging the same pathway the body uses normally — so GH tends to come out in natural pulses. Ipamorelin works through a completely different receptor: it mimics ghrelin and activates the ghrelin / GH-secretagogue receptor (GHS-R1a). A frequently cited feature of ipamorelin is selectivity — in studies it raised GH with relatively little effect on cortisol, ACTH, or prolactin, which set it apart from earlier secretagogues.
The difference that matters most day-to-day, though, is regulatory: neither is a currently FDA-approved medicine, and the details of why differ for each compound, as the next sections explain.
Are sermorelin and ipamorelin FDA-approved?
Neither is an FDA-approved product today, but the histories are different. Sermorelin was once approved, marketed as Geref for evaluating and treating growth hormone deficiency in children. The manufacturer voluntarily withdrew it from the market in 2008. Per the FDA's own Federal Register determination, that withdrawal was for commercial reasons — the product was explicitly found NOT to have been withdrawn for reasons of safety or effectiveness. Because of that, and because sermorelin has a USP monograph, it is still prepared today by 503A compounding pharmacies, though no FDA-approved branded sermorelin product currently exists.
Ipamorelin has never been FDA-approved for any indication. It appeared on the FDA's interim Category-2 list of bulk drug substances (the tier flagged for significant safety questions) but was removed from that list in September 2024 after the party that nominated it withdrew the nomination; it is now among the peptides under Pharmacy Compounding Advisory Committee review, so its compounding status is unsettled rather than settled in either direction.
In short: sermorelin sits on firmer regulatory footing for compounding, while ipamorelin's status is in flux. Neither is an approved, vetted finished drug you can be prescribed off a pharmacy shelf the way an FDA-approved medicine is.
What does the human evidence actually show?
This is where honesty matters, because clinic marketing often outruns the data. Sermorelin has the longer human track record of the two: as a GHRH analog it was studied in children for GH deficiency, and smaller adult studies have looked at GH and IGF-1 restoration, sleep, and body composition in older adults with relative GH decline. But large, long-term randomized controlled trials for the anti-aging and physique uses it is now marketed for are lacking, so those specific benefits remain less well established than the data for recombinant GH.
Ipamorelin's human evidence is thinner still. Its most rigorous published human study was a 2014 Phase 2 trial testing it for postoperative ileus (slowed gut function after bowel surgery), not for anti-aging or muscle gain. In that trial ipamorelin was well tolerated, but it did NOT meet its primary efficacy endpoint, and no sponsor has advanced it through a full Phase 3 program. Much of what is claimed for ipamorelin in wellness settings rests on its GH-releasing pharmacology rather than on outcome trials in people.
The practical takeaway: both reliably raise short-term GH in studies, but rigorous human evidence that this translates into the body-composition, recovery, or longevity benefits they are marketed for is limited for sermorelin and weaker for ipamorelin.
How do the side-effect profiles and anti-doping status compare?
Both are generally described as well tolerated in the studies that exist, with the most common reports being injection-site reactions and, for secretagogues as a class, the theoretical considerations that come with raising GH and IGF-1 (such as fluid retention, joint discomfort, or effects on insulin sensitivity). Ipamorelin's selectivity for GH over cortisol and prolactin is often highlighted as a tolerability advantage versus older secretagogues, but long-term safety data for both compounds in the populations using them are limited, and any individual's risk picture is a conversation for a physician.
For athletes the line is sharp and identical for both: the World Anti-Doping Agency prohibits GHRH analogues and growth hormone secretagogues under Section S2 of its Prohibited List, banned at all times — in and out of competition. Sermorelin and ipamorelin both fall in that class. A positive test is an anti-doping rule violation, so anyone in a drug-tested sport should treat both as disqualifying.
Tracking either compound on PeptidePanel
Whichever secretagogue a qualified clinician chooses to prescribe and monitor, the day-to-day discipline is the same: log doses, watch the biomarkers that matter (IGF-1, fasting glucose, and how you actually feel — sleep, recovery, body composition over time), and catch side effects early. PeptidePanel is the neutral tracking layer for exactly that — it records the protocol your clinician sets, charts your bloodwork against reference ranges, and reminds you when a dose or a lab is due.
PeptidePanel does not sell, source, supply, endorse, or prescribe any compound, and nothing here is medical advice. Both peptides discussed on this page are without a current FDA-approved finished product, and the decision to use either belongs with a licensed physician who understands the risks.